一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Cardiology Research >>article

Cardiology Research

IF: 1.39
Download PDF

A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations.

Published:1 April 2013 DOI: 10.4021/cr270w PMID: 28352420
Hua Ling,?John T Luoma,?Daniel Hilleman

Abstract

Fenofibrate is a third-generation fibric acid derivative indicated as a monotherapy to reduce elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, and apolipoprotein B; to increase high-density lipoprotein cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia; and to reduce triglycerides in patients with severe hypertriglyceridemia. In this review, the key characteristics of available fenofibrate formulations are examined. A literature search was conducted, focusing on comparative studies examining bioavailability, food effects, absorption, and lipid efficacy. Fenofibrate is highly lipophilic, virtually insoluble in water, and poorly absorbed. Coadministration with meals was necessary to maximize bioavailability of early formulations. Micronized and nanoparticle formulations of fenofibrate with reduced particle sizes were developed, resulting in greater solubility, improved bioavailability, and in some cases, the ability to be given irrespective of food. A recently introduced hydrophilic choline salt of fenofibric acid also can be taken without regard to meals, is absorbed throughout the gastrointestinal tract, has the highest bioavailability among marketed formulations, and is approved for coadministration with a statin. Differences in bioavailability of fenofibrate formulations have resulted in low-dose (40 - 67) mg and standard-dose (120 - 200 mg) formulations. Different formulations are not equivalent on a milligram-to-milligram basis. In order to prevent medication errors, resulting in underdosing or overdosing with attendant consequences, it is important for healthcare providers to recognize that the formulations of fenofibrate and fenofibric acid that are currently available vary substantially in relation to food effect, equivalency on a milligram-to-milligram basis, and indication to be coadministered with a statin.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Fenofibrate 49562-28-9 C20H21ClO4 784 suppliers $5.00-$602.00
Fenofibric acid 42017-89-0 C17H15ClO4 460 suppliers $5.00-$1500.00
CHOLINE 62-49-7 C5H14NO 91 suppliers $505.54-$505.54

Similar articles

IF:5.4

Desonide: a review of formulations, efficacy and safety.

ACS Applied Energy Materials Nr Kahanek, Cg Gelbard,etc Published: 1 July 2008
岢岚县| 镇安县| 宿松县| 历史| 安义县| 当涂县| 晋宁县| 庆阳市| 嘉义市| 郎溪县| 阳原县| 诏安县| 五大连池市| 龙江县| 班戈县| 海阳市| 日喀则市| 玉溪市| 白玉县| 沭阳县| 武威市| 松滋市| 鹿泉市| 桂平市| 岑巩县| 扎兰屯市| 长沙县| 巴林左旗| 仙居县| 光山县| 亚东县| 普兰县| 前郭尔| 云林县| 徐州市| 佳木斯市| 兰溪市| 临泉县| 浑源县| 六盘水市| 珠海市|